The World’s First ‘Reverse-Ageing’ Human Trial Has Begun — And It Could Change Medicine Forever

For

decades, reversing ageing has belonged more to the realm of science fiction than modern medicine. Researchers could slow aging in laboratory animals, extend lifespan in worms and mice, and identify biological processes that deteriorate over time. But actually turning older cells into younger, healthier versions of themselves inside a living human body remained out of reach. That may be starting to change.

First Human Trial Of Reverse Ageing Begins

In a landmark moment for longevity science, Boston-based Life Biosciences has dosed the first patient in a Phase 1 clinical trial of ER-100, an experimental therapy designed to rejuvenate damaged cells by resetting part of their biological age. The study marks the first time a cellular reprogramming treatment has entered human clinical testing.The treatment is not aimed at making people look younger or live forever. For now, researchers are targeting two serious eye conditions, open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION), both of which damage retinal ganglion cells, the nerve cells responsible for transmitting visual information from the eye to the brain. What makes ER-100 different from conventional medicines is the science behind it.

The therapy is based on a breakthrough discovery made by Japanese stem-cell scientist Shinya Yamanaka, who showed that mature cells can be reprogrammed into a more youthful state using a set of proteins now known as the Yamanaka factors. Rather than using all four factors, Life Biosciences employs a carefully controlled combination of three, OCT4, SOX2 and KLF4, collectively known as OSK, while excluding c-MYC, a factor associated with increased cancer risk.

What Is The Goal Of Reverse Ageing Trial?

The goal is not to transform cells back into embryonic stem cells. Instead, scientists hope to perform what is known as 'partial reprogramming,' nudging damaged cells toward a younger biological state while preserving their identity and function. If successful, the process could restore cellular performance that has been lost through ageing, disease or injury.The excitement surrounding the trial stems from years of promising laboratory results. In animal studies, partial cellular reprogramming has been shown to restore youthful patterns of gene activity and improve visual function. Life Biosciences has reported encouraging results in non-human primates, helping pave the way for regulatory approval and human testing. Still, scientists caution that this is only the beginning.

Reverse-Ageing Study

The current study is a first-in-human Phase 1 trial, meaning its primary purpose is to evaluate safety and tolerability rather than prove effectiveness. Participants will receive a single dose of ER-100 and will be monitored extensively, with long-term follow-up planned for up to five years. Researchers will assess side effects, immune responses and changes in visual function.

Not everyone is convinced the technology will work as hoped. Some experts have raised concerns about whether reprogrammed cells will function properly in diseased tissue and whether altering cellular identity could create unforeseen risks. Others argue that longevity science has sometimes moved faster than the evidence. Even so, few dispute the significance of this moment.For the first time, a therapy designed to reverse aspects of cellular aging is being tested in a human being. Whether ER-100 ultimately succeeds or fails, the trial represents a historic turning point, one that could reveal whether age-related decline is something medicine can not only slow, but potentially reverse. The first meaningful results are expected later in 2026. Until then, the world of longevity research will be watching closely.